Isolation of p53 protein from the serum of colon cancer and non-cancer patients

I. Zusman, R. Zusman, D. Korol, B. Sandler, H. Ben-Hur, D. Bass, A. Mashiah, B. Lifschitz-Mercer, P. Smirnoff, J. Glick

Research output: Contribution to journalArticlepeer-review


A new method for the isolation of p53 protein from the sera of cancer and non-cancer patients has been developed. The method is based on the utilization of a new modification of a support for affinity chromatography in the form of gel fiberglass (GFG) (R. Zusman, patent applications, Israel, 1992; USA 1993). The sera were percolated through GFG columns with entrapped rabbit IgG generated against the colon cancer antigens. Tumor-associated antigens were eluted from sera of cancer patients in large amounts, up to 2.4 mg/ml serum/column. Concentrations of these antigens in different sera and their affinity to anti-tumoral antibodies were detected by ELISA. Western immunoblotting with commercial monoclonal antibodies and SDS-PAGE identified the isolated antigens as the p53 protein. This protein has been isolated in the highest concentration yet reported from the serum of cancer patients, up to 1 mg/ml. The same protein has been found in the serum of healthy people and non-cancer patients but in significantly lower concentrations. Isolation of p53 protein from sera of non-cancer patients confirms the opinion of some investigators that this protein should be considered not only as an oncogene but also as a protein correlated with different changes in the cell cycle.

Original languageEnglish
Pages (from-to)679-683
Number of pages5
JournalOncology Reports
Issue number4
StatePublished - 1995
Externally publishedYes


  • Affinity chromatography
  • Colon cancer
  • Gel fiberglass
  • IgG
  • P53 protein isolation
  • Supports
  • Tumor-associated antigens


Dive into the research topics of 'Isolation of p53 protein from the serum of colon cancer and non-cancer patients'. Together they form a unique fingerprint.

Cite this